Table 4 SRR (95% CI) of the risk of subsequent cancers in patients exposed to group I pharmaceuticals by study design.

Cyclosporine

Skin

Cohort

10^{20,21,22,24,26,27,28,29,30,31}

1.23 (1.00–1.51)^H

Case–control

3^23,25,32

2.03 (0.79–5.23)^H

Hematologic

Cohort

5^{20,33,34,36,37}

0.94 (0.83–1.07)^L

Case–control

1³⁵

0.90 (0.20–5.80)

Azathioprine

Skin

Cohort

9^{21,22,24,27,28,29,31,38,40}

1.32 (1.11–1.58)^L

Case–control

4^23,25,39,41

2.61 (1.35–5.05)^H

Hematologic

Cohort

10^{33,34,36,37,38,42,44,45,46,47}

1.53 (1.10–2.12)^H

Case–control

2^35,43

1.30 (0.61–2.78)^L

Cyclophosphamide

Bladder

Case–control

3^48,49,50

2.87 (1.32–6.23)^I

Hematologic

Cohort

1⁴⁴

2.09 (0.69–6.30)

Case–control

6^{43,50,51,52,53,54}

2.50 (1.61–3.90)^I

Busulfan

Hematologic

Cohort

1⁵⁶

8.64 (2.44–30.60)

RCT

1⁵⁵

4.48 (1.11–27.10)

Chlorambucil

Hematologic

Case–control

2^52,54

1.32 (0.81–2.16)^L

Methoxsalen + UV

Skin

Case–control

1⁵⁷

6.50 (1.40–31.40)

Melphalan

Hematologic

Case–control

3^51,52,58

4.43 (1.30–15.15)^H

MOPP

Lung

Case–control

1⁵⁹

5.00 (2.10–13.60)

Etoposide

Hematologic

Case–control

1⁶⁰

2.70 (1.20–6.00)

Thiotepa

Hematologic

Case–control

1⁵²

1.82 (1.09–3.03)